FRIDAY, Feb. 14, 2020 — A clinical trial of the weight-loss drug Belviq (lorcaserin) shows an association with an increased risk for cancer, and the U.S. Food and Drug Administration is requesting that its maker withdraw the drug from the U.S. market.
Eisai Inc. has already “submitted a request to voluntarily withdraw the drug,” Janet Woodcock, M.D., who directs the FDA Center for Drug Evaluation and Research, noted in a statement issued Thursday. Now, “we’re taking steps to notify the public,” she said, adding that “our review of the full clinical trial results shows that the potential risk of cancer associated with the drug outweighs the benefit of treatment.”
Woodcock said the FDA is advising that “patients should stop using the medication Belviq and Belviq XR and talk to their health care professionals about other treatment options for weight loss. Health care professionals should stop prescribing and dispensing Belviq and Belviq XR.”
According to the FDA, Belviq was first approved in 2012 as an add-on therapy to help aid weight loss, along with diet and exercise, in people who were obese or overweight. Contingent on approval, the FDA ordered a randomized, placebo-controlled trial be conducted involving 12,000 people tracked for more than five years. The trial wrapped up in June 2018, and the data showed that while 7.1 percent of those taking a “dummy” placebo developed cancer, that number rose to 7.7 percent among those taking Belviq.
People who have already taken Belviq should stop taking it, but “the FDA is not recommending special screening for patients who have taken Belviq,” Woodcock said.
© 2020 HealthDay. All rights reserved.
Posted: February 2020